Marina Chiara Garassino to Protein Kinase Inhibitors
This is a "connection" page, showing publications Marina Chiara Garassino has written about Protein Kinase Inhibitors.
Connection Strength
3.314
-
Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program. Eur J Cancer. 2021 05; 149:235-248.
Score: 0.546
-
Afatinib for lung cancer: let there be light? Lancet Oncol. 2014 Feb; 15(2):133-4.
Score: 0.331
-
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol. 2013 Sep; 14(10):981-8.
Score: 0.320
-
Emerging toxicities in the treatment of non-small cell lung cancer: ocular disorders. Cancer Treat Rev. 2014 Feb; 40(1):197-203.
Score: 0.320
-
To target or not to target, that is the question. J Clin Oncol. 2013 Mar 20; 31(9):1254.
Score: 0.310
-
Testing epidermal growth factor receptor mutations in patients with non-small-cell lung cancer to choose chemotherapy: the other side of the coin. J Clin Oncol. 2011 Oct 01; 29(28):3835-7; author reply 3837-9.
Score: 0.281
-
Biological and clinical features in predicting efficacy of epidermal growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis. Anticancer Res. 2009 Jul; 29(7):2691-701.
Score: 0.242
-
Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. N Engl J Med. 2020 09 03; 383(10):931-943.
Score: 0.129
-
CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3). J Clin Oncol. 2018 09 10; 36(26):2702-2709.
Score: 0.113
-
Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer. Handb Exp Pharmacol. 2018; 249:63-89.
Score: 0.109
-
Uncommon mutations in epidermal growth factor receptor and response to first and second generation tyrosine kinase inhibitors: A case series and literature review. Lung Cancer. 2018 01; 115:135-142.
Score: 0.108
-
Treatment in EGFR-mutated non-small cell lung cancer: how to block the receptor and overcome resistance mechanisms. Tumori. 2017 Jul 31; 103(4):325-337.
Score: 0.105
-
Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations. Crit Rev Oncol Hematol. 2015 May; 94(2):213-27.
Score: 0.088
-
Targeting the MET gene for the treatment of non-small-cell lung cancer. Crit Rev Oncol Hematol. 2014 Feb; 89(2):284-99.
Score: 0.082
-
Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4). J Thorac Oncol. 2023 08; 18(8):1031-1041.
Score: 0.039
-
Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial. J Thorac Oncol. 2022 09; 17(9):1086-1097.
Score: 0.037
-
Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies. Lung Cancer. 2022 08; 170:41-51.
Score: 0.037
-
Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer. Lung Cancer. 2021 07; 157:9-16.
Score: 0.034
-
First Case Report of Pregnancy on Alectinib in a Woman With Metastatic ALK-Rearranged Lung Cancer: A Case Report. J Thorac Oncol. 2021 05; 16(5):873-877.
Score: 0.034
-
Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib. Sci Rep. 2018 01 17; 8(1):948.
Score: 0.027
-
Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy number. J Thorac Oncol. 2013 Dec; 8(12):e105-6.
Score: 0.021